Neuphoria Therapeutics (NEUP) Cash & Equivalents (2020 - 2026)
Neuphoria Therapeutics (NEUP) posted quarterly Cash & Equivalents of $19.4 million for Q1 2026, up 14.06% year-over-year from $17.0 million in Q1 2025, and down 12.31% quarter-over-quarter from $22.2 million in Q4 2025.
Neuphoria Therapeutics (NEUP) Cash & Equivalents (2020 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Cash & Equivalents for 7 consecutive years, with $19.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Equivalents rose 14.06% year-over-year to $19.4 million; the TTM figure through Mar 2026 stood at $19.4 million (up 14.06% YoY), while the FY2025 annual figure was $14.2 million, up 12.71% from the prior year.
- Cash & Equivalents slipped to $19.4 million in Q1 2026 per NEUP's latest filing, from $22.2 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $24.0 million in Q2 2022 and bottomed at $4.3 million in Q4 2024.
- Historically, Cash & Equivalents has averaged $13.4 million across 5 years, with a median of $12.6 million in 2024.
- Annual changes were most pronounced in 2024 — Cash & Equivalents tumbled 57.22% — and 2025, when it surged 410.3%.
- Neuphoria Therapeutics' Cash & Equivalents stood at $24.0 million in 2022, then sank by 57.76% to $10.2 million in 2023, then plunged by 57.22% to $4.3 million in 2024, then soared by 410.3% to $22.2 million in 2025, then dropped by 12.31% to $19.4 million in 2026.
- Business Quant data shows NEUP's Cash & Equivalents at $19.4 million in Q1 2026, $22.2 million in Q4 2025, and $13.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.72 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.71 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.93 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 544.80 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 811.99 Mn |
| 10 | Neuphoria Therapeutics | 21.28 Mn | 1.84 Mn | - | 19.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.44 Mn |
| Dec 31, 2025 | 22.17 Mn |
| Sep 30, 2025 | 13.60 Mn |
| Jun 30, 2025 | 14.21 Mn |
| Mar 31, 2025 | 17.04 Mn |
| Dec 31, 2024 | 4.34 Mn |
| Sep 30, 2024 | 8.08 Mn |
| Jun 30, 2024 | 12.61 Mn |
| Mar 31, 2024 | 8.43 Mn |
| Dec 31, 2023 | 10.15 Mn |
| Sep 30, 2023 | 8.14 Mn |
| Jun 30, 2023 | 12.20 Mn |
| Jun 30, 2022 | 24.04 Mn |
| Jun 30, 2021 | 21.95 Mn |
| Jun 30, 2020 | 3.00 Mn |